Business

Curium™ announces FDA approval of BEXLUTRY lutetium Lu 177 dotatate injection for adults with SSTR-positive GEP-NETs

Financial Post · September 14, 2026 at 5:52 p.m.

BEXLUTRY is the first radioligand equivalent for the treatment of GEP-NETs in adults and the first radioligand therapy from Curium™ approved by the FDA BOSTON, Sept.

14, 2026 (GLOBE NEWSWIRE) — Curium™ announced today th

Read the full article on Financial Post ›

5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on financialpost.com — the content belongs to Financial Post.

Curium™ announces FDA approval of BEXLUTRY lutetium Lu 177 dotatate injection for adults with SSTR-positive GEP-NETs

More from Financial Post

Prime Drink Group Announces Subscription Receipt Financing and Closing of Second Tranche of Private Placement of Units

Solera | Hollander Showcases the Next Era of Automotive Recycling at ARA 2026

Purecore Upsizes Non-Brokered Private Placement to $3.5M

David Pearson Appointed President of Anthem Properties Group

More in Business

Prime Drink Group Announces Subscription Receipt Financing and Closing of Second Tranche of Private Placement of Units

Solera | Hollander Showcases the Next Era of Automotive Recycling at ARA 2026

Purecore Upsizes Non-Brokered Private Placement to $3.5M

David Pearson Appointed President of Anthem Properties Group

AGI Third Quarter 2026 Results Release Date and Conference Call

Black Diamond Group Limited to Announce Third Quarter 2026 Financial Results and Host Conference Call